GI Pharmacology · Module 8 of 8

Pancreatic and Nutritional Pharmacology

Acute pancreatitis management · Enzyme replacement · Somatostatin analogues · Refeeding syndrome · Micronutrient deficiencies

Acute pancreatitis: aggressive IV fluid resuscitation with lactated Ringer's preferred over normal saline (WATERFALL trial: lower SIRS rate); 250–500 mL/hour first 12–24 hours, target HR <120, MAP >65, urine output >0.5 mL/kg/hour; avoid over-resuscitation (abdominal compartment syndrome); early enteral nutrition within 24–48 hours (superior to parenteral: preserves gut barrier, reduces infection); nasojejunal if nasogastric not tolerated; antibiotics NOT indicated prophylactically (no mortality benefit in RCTs, selects resistant organisms and fungal superinfection); antibiotics only for confirmed or suspected infected pancreatic necrosis (imipenem or meropenem for pancreatic tissue penetration) or extrapancreatic infection.
Exocrine pancreatic insufficiency (EPI): diagnosis when >90% of exocrine function lost (steatorrhea, weight loss, low fecal elastase); PERT is mainstay — enteric-coated porcine lipase/amylase/protease; minimum 40,000–50,000 units lipase per main meal, 20,000–25,000 per snack; take with meals (divided beginning to middle); enteric coating protects against gastric acid; add PPI if duodenal pH remains low (reduces bicarbonate secretion in chronic pancreatitis → coat may not dissolve); do not crush or chew; supplement fat-soluble vitamins A, D, E, K (vitamin D most clinically important — monitor 25-OH-D, target >30 ng/mL).
Functional pancreatic neuroendocrine tumors — somatostatin analogues (octreotide, lanreotide) are the cornerstone of medical management; bind somatostatin receptors (subtypes 2 and 5) → suppress VIP (VIPoma: controls profuse secretory diarrhea), glucagon (glucagonoma: improves necrolytic migratory erythema), serotonin (carcinoid syndrome: reduces flushing and diarrhea); monthly LAR/autogel formulations; class AEs: cholelithiasis (up to 50% on long-term therapy — monitor with gallbladder ultrasound), steatorrhea, glucose elevation; diazoxide for insulinoma (ATP-sensitive K⁺ channel opener → hyperpolarizes beta cells → suppresses insulin secretion; causes fluid retention — add diuretic; watch for paradoxical hypoglycemia if adding octreotide); ZES/gastrinoma: high-dose PPI (omeprazole 60–120 mg/day) — far above standard PUD doses.
Refeeding syndrome: mechanism — during starvation, total body PO₄/K⁺/Mg²⁺ depleted while serum levels near-normal; on restarting nutrition, insulin surge drives electrolytes into cells → severe hypophosphatemia (most dangerous: impairs ATP synthesis → respiratory failure from diaphragm weakness, arrhythmias, seizures); risk factors: BMI <16, >10% weight loss in 2 months, negligible intake >5 days, alcoholism, anorexia nervosa; prevention: correct electrolytes before starting; begin at 10 kcal/kg/day, increase over 4–7 days; monitor daily electrolytes; ALWAYS give thiamine before glucose in malnourished patients.
Thiamine before glucose (absolute rule): thiamine is a cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase; deficiency plus glucose load → Wernicke's encephalopathy (nystagmus, ophthalmoplegia, ataxia, confusion) → can progress to irreversible Korsakoff syndrome (permanent amnesia); give thiamine 100–200 mg IV before any glucose-containing fluid or nutritional support in any malnourished patient; key micronutrients: B12 (megaloblastic anemia + subacute combined degeneration; IM hydroxocobalamin if no intrinsic factor); folate (megaloblastic anemia, no neurological features; oral 5 mg daily); iron (microcytic anemia; oral ferrous sulfate; IV iron if malabsorption); zinc (wound healing, taste loss; IBD and alcoholism); selenium (cardiomyopathy on long-term PN without trace elements).

ATP = adenosine triphosphate · CCK = cholecystokinin · EPI = exocrine pancreatic insufficiency · IBD = inflammatory bowel disease · LAR = long-acting release · MAP = mean arterial pressure · NET = neuroendocrine tumor · PERT = pancreatic enzyme replacement therapy · PN = parenteral nutrition · PPI = proton pump inhibitor · PUD = peptic ulcer disease · RCT = randomized controlled trial · SIRS = systemic inflammatory response syndrome · VIP = vasoactive intestinal peptide · ZES = Zollinger-Ellison syndrome

Acute Pancreatitis: Key Pharmacological Decisions

Fluid Resuscitation

Lactated Ringer's Preferred

Lactated Ringer's preferred over normal saline (WATERFALL trial: lower SIRS rate); 250–500 mL/hour for first 12–24 hours
Targets: HR <120 bpm, MAP >65 mmHg, urine output >0.5 mL/kg/hour, hematocrit falling toward normal
Avoid over-resuscitation: abdominal compartment syndrome risk with excessive fluid in retroperitoneal inflammation
Switch to maintenance once hemodynamically stable; reassess frequently

Antibiotics

Do NOT Use Prophylactically

Prophylactic antibiotics: no mortality benefit in multiple RCTs; select resistant organisms and promote fungal superinfection; not recommended regardless of severity
Indicated only for: infected pancreatic necrosis (clinical deterioration + fever + gas within necrosis on imaging) or extrapancreatic infection (cholangitis, UTI, pneumonia)
For infected necrosis: imipenem or meropenem (adequate pancreatic tissue penetration); obtain cultures first via EUS-guided FNA to guide de-escalation

Nutrition

Early Enteral > Parenteral

Early enteral nutrition within 24–48 hours in severe pancreatitis: superior to parenteral (preserves gut barrier, reduces bacterial translocation, fewer infection complications)
Nasogastric feeding acceptable if tolerated; nasojejunal (distal to ligament of Treitz) preferred if gastroparesis limits gastric feeding
Parenteral nutrition only when enteral access cannot be established; associated with higher infection rates, hyperglycemia, and catheter complications than enteral route

Somatostatin Analogues and Functional Neuroendocrine Tumor Management

Tumor	Excess Hormone	Drug	Key Clinical Points
VIPoma	Vasoactive intestinal peptide (VIP)	Octreotide or lanreotide	Rapidly controls profuse secretory diarrhea (>3 L/day); allows fluid/electrolyte replacement and stabilization before surgical resection
Glucagonoma	Glucagon	Octreotide or lanreotide	Improves necrolytic migratory erythema and glucose intolerance by suppressing glucagon hypersecretion; nutritional support also required (protein deficiency contributes to skin lesions)
Carcinoid syndrome	Serotonin (+ others)	Octreotide LAR or lanreotide autogel (monthly)	Reduces flushing and diarrhea; demonstrated antiproliferative activity in well-differentiated NETs; cholelithiasis in up to 50% on long-term therapy — monitor with ultrasound
Insulinoma	Insulin	Diazoxide (ATP-sensitive K⁺ channel opener)	Hyperpolarizes beta cells → suppresses calcium influx → inhibits insulin secretion; causes Na⁺/water retention (add diuretic); caution adding octreotide (also suppresses glucagon → can worsen hypoglycemia)
Gastrinoma (ZES)	Gastrin	High-dose PPI (omeprazole/esomeprazole 60–120 mg/day)	Doses far above standard PUD doses required to suppress massive acid output; controls ulcers and diarrhea reliably; surgical resection pursued when feasible (only potential cure)

Refeeding Syndrome and High-Yield Micronutrient Deficiencies

Refeeding Syndrome

Hypophosphatemia on Restarting Nutrition

Mechanism: starvation depletes total body PO₄/K⁺/Mg²⁺ (serum levels near-normal due to redistribution); reintroducing carbohydrate → insulin surge → drives electrolytes intracellularly → severe hypophosphatemia
Most dangerous: hypophosphatemia impairs ATP synthesis → respiratory failure (diaphragm weakness — leading cause of death), arrhythmias, hemolytic anemia, rhabdomyolysis, seizures
Risk factors: BMI <16 kg/m², >10% body weight loss over 2 months, negligible intake >5 days, alcoholism, anorexia nervosa, prolonged nil by mouth
Prevention: measure and correct PO₄/K⁺/Mg²⁺ before starting; begin at ≤10 kcal/kg/day; increase gradually over 4–7 days; monitor electrolytes daily; thiamine before any glucose

High-Yield Micronutrient Deficiencies

Presentations and Treatment

Thiamine (B1): Wernicke's (nystagmus, ophthalmoplegia, ataxia, confusion) → Korsakoff (irreversible amnesia); give IV 100–200 mg before any glucose in malnourished patients
Vitamin B12: megaloblastic anemia + subacute combined degeneration (posterior + lateral cord demyelination); IM hydroxocobalamin if pernicious anemia or terminal ileal disease (no intrinsic factor or absorption site)
Folate: megaloblastic anemia without neurological features; oral folate 5 mg daily; do not give B12 without first checking B12 level (can mask B12 deficiency neurologically)
Iron: microcytic hypochromic anemia; oral ferrous sulfate first-line; IV iron sucrose or ferric carboxymaltose if malabsorption (IBD, post-bariatric)
Zinc: impaired wound healing, anosmia, ageusia; common in IBD and alcoholism; selenium: cardiomyopathy (Keshan disease) with long-term PN without trace elements

Critical Rule — Thiamine Before Glucose in Malnourished Patients

In any malnourished patient — alcoholism, anorexia nervosa, prolonged starvation, any patient presenting with nutritional neglect — thiamine 100 to 200 mg must be given intravenously before any glucose-containing fluid, food, or nutritional support. Glucose without thiamine in a thiamine-deficient patient floods pyruvate dehydrogenase with substrate it cannot process, precipitating Wernicke's encephalopathy. Without prompt thiamine replacement, Wernicke's progresses to Korsakoff syndrome — permanent anterograde and retrograde amnesia — which is irreversible. This rule applies without exception: do not wait for a thiamine level result before giving thiamine.

Chapter 27 Complete — GI & Pulmonary & Renal Pharmacology

This chapter has covered the full breadth of gastrointestinal and hepatopancreatic pharmacology: from acid suppression (PPIs and H2 blockers, H. pylori eradication) to motility (prokinetics and antiemetics), bowel inflammation (5-ASA agents, corticosteroids, thiopurines, methotrexate, anti-TNF biologics, vedolizumab, ustekinumab, risankizumab, JAK inhibitors), lower GI function (laxatives, PAMORAs, antidiarrheals, CDI, IBS), hepatology (viral hepatitis NAs and DAAs, acute liver failure, alcoholic hepatitis, MASH, PBC, hepatic encephalopathy), and pancreatic and nutritional pharmacology (enzyme replacement, somatostatin analogues, refeeding syndrome, micronutrient deficiencies).

The cross-cutting themes that unify this chapter: (1) drug selectivity through pharmacokinetic design — PPIs as prodrugs activated in acid, PAMORAs excluded from the CNS by charge or P-gp, mesalamine delivered site-specifically, rifaximin and oral vancomycin acting intraluminally without systemic exposure; (2) fatal drug interactions requiring pre-prescription screening — allopurinol plus thiopurine, sofosbuvir plus amiodarone, eluxadoline post-cholecystectomy, methotrexate in pregnancy; (3) the principle that pharmacological management complements but does not substitute for addressing the underlying cause — abstinence in alcoholic liver disease, weight loss in MASH, precipitant correction in hepatic encephalopathy, surgical resection in functional NETs; (4) time-critical interventions — N-acetylcysteine within 8 hours of acetaminophen overdose, thiamine before glucose in malnutrition, prednisolone assessment with the Lille score at day 7.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter on Gastrointestinal Pharmacology	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill; 2023
Tenner S et al.	American College of Gastroenterology guideline: management of acute pancreatitis	Am J Gastroenterol. 2013;108(9):1400–1415
de-Madaria E et al.	Lactated Ringer’s solution versus normal saline for acute pancreatitis (WATERFALL trial)	N Engl J Med. 2022;387(11):982–991
Weimann A et al.	ESPEN guideline: clinical nutrition in surgery	Clin Nutr. 2017;36(3):623–650
Dominguez-Munoz JE	Pancreatic exocrine insufficiency: diagnosis and treatment	J Gastroenterol Hepatol. 2011;26(Suppl 2):12–16
Kvols LK et al.	Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue	N Engl J Med. 1986;315(11):663–666
Stehling LC, Simon TL	The role of diazoxide in the medical management of insulinoma	Arch Intern Med. 1995;155(3):357–361
Crook MA et al.	The importance of the refeeding syndrome	Nutrition. 2001;17(7–8):632–637
National Institute for Health and Care Excellence	Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)	NICE 2006 (updated 2017)